Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leif Erhardt

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Current Controlled Trials in Cardiovascular Medicine|November 21, 2001
Design of a trial evaluating myocardial cell protection with cariporide, an inhibitor of the transmembrane sodium-hydrogen exchanger: the Guard During Ischemia Against Necrosis (GUARDIAN) trialPierre Theroux, Bernard R Chaitman, Leif Erhardt, et al.
Journal of the American College of Cardiology|April 25, 2006
A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the "patient journey") in patients with heart failure: a report from the Carvedilol Or Metoprolol European Trial (COMET)John G F Cleland, Andrew Charlesworth, Jacobus Lubsen, et al.
Contemporary Clinical Trials|May 11, 2007
Rationale, design, and methods for the risk evaluation and communication health outcomes and utilization trial (REACH OUT)Joshua S Benner, Spencer B Cherry, Leif Erhardt, et al.
European Journal of Heart Failure|August 25, 2007
Effect of carvedilol and metoprolol on the mode of death in patients with heart failureWillem J Remme, John G Cleland, Leif Erhardt, et al.
European Journal of Heart Failure|August 10, 2005
Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practiceJohn McMurray, Alain Cohen-Solal, Rainer Dietz, et al.
Cardiovascular Drugs and Therapy|May 27, 2004
A description of the clinical characteristics at baseline of patients recruited into the Carvedilol or Metoprolol European Trial (COMET)John G F Cleland, Kevin Goode, Leif Erhardt, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Current Controlled Trials in Cardiovascular Medicine|November 21, 2001
Design of a trial evaluating myocardial cell protection with cariporide, an inhibitor of the transmembrane sodium-hydrogen exchanger: the Guard During Ischemia Against Necrosis (GUARDIAN) trialPierre Theroux, Bernard R Chaitman, Leif Erhardt, et al.
Journal of the American College of Cardiology|April 25, 2006
A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the "patient journey") in patients with heart failure: a report from the Carvedilol Or Metoprolol European Trial (COMET)John G F Cleland, Andrew Charlesworth, Jacobus Lubsen, et al.
Contemporary Clinical Trials|May 11, 2007
Rationale, design, and methods for the risk evaluation and communication health outcomes and utilization trial (REACH OUT)Joshua S Benner, Spencer B Cherry, Leif Erhardt, et al.
European Journal of Heart Failure|August 25, 2007
Effect of carvedilol and metoprolol on the mode of death in patients with heart failureWillem J Remme, John G Cleland, Leif Erhardt, et al.
European Journal of Heart Failure|August 10, 2005
Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practiceJohn McMurray, Alain Cohen-Solal, Rainer Dietz, et al.
Cardiovascular Drugs and Therapy|May 27, 2004
A description of the clinical characteristics at baseline of patients recruited into the Carvedilol or Metoprolol European Trial (COMET)John G F Cleland, Kevin Goode, Leif Erhardt, et al.
Pageof 3